U.S. markets closed

Reata Pharmaceuticals, Inc. (RETA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
172.36+0.04 (+0.02%)
At close: 04:00PM EDT
172.36 0.00 (0.00%)
After hours: 04:23PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close172.32
Bid172.36 x 1100
Ask172.40 x 1100
Day's Range172.32 - 172.46
52 Week Range21.83 - 172.46
Avg. Volume954,093
Market Cap6.566B
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-2.62
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est172.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RETA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Reata Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/15/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • Insider Monkey

    Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio?

    TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]

  • Business Wire

    Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

    PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen").

  • Simply Wall St.

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future

    Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would...